BIO - Bio-Rad Laboratories, Inc.
302.21 -0.27 (-0.09%)
Pre-Market: 8:35AM EDT
| Previous Close | 298.43 |
| Open | 298.72 |
| Bid | 0.00 x 800 |
| Ask | 302.69 x 800 |
| Day's Range | 298.06 - 303.25 |
| 52 Week Range | 220.05 - 345.15 |
| Volume | 77,948 |
| Avg. Volume | 201,389 |
| Market Cap | 8.974B |
| Beta (3Y Monthly) | 1.46 |
| PE Ratio (TTM) | 15.90 |
| EPS (TTM) | 19.00 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 368.75 |
- Insider Monkey•4 days ago
Here’s What Hedge Funds Think About Bio-Rad Laboratories, Inc. (BIO)
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. Trends reversed 180 degrees during the first quarter amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
- Simply Wall St.•4 days ago
What Kind Of Shareholder Appears On The BIOTON S.A.'s (WSE:BIO) Shareholder Register?
The big shareholder groups in BIOTON S.A. (WSE:BIO) have power over the company. Institutions will often hold stock in...
- American City Business Journals•6 days ago
9 major Bay Area tech employers pay a typical worker more than $200K per year
Large Bay Area tech employers that pay a typical employee more than $200,000 per year include the typical suspects like Google parent Alphabet Inc., Facebook and Netflix. But several companies that are lesser-known outside Silicon Valley also pay top dollar for talent.
- Markit•8 days ago
See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
Bio Rad Laboratories Inc NYSE:BIOView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BIO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIO. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $298 million over the last one-month into ETFs that hold BIO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•11 days ago
Bio-Rad (BIO) Down 6.9% Since Last Earnings Report: Can It Rebound?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•15 days ago
Bio-Rad to Participate in Goldman Sachs Annual Global Healthcare Conference on June 11
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, at 10:40 AM , at the Terranea Resort, Rancho Palos Verdes, California.
- Zacks•18 days ago
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
Bio-Rad (BIO) continues to witness high investor confidence on strength in the Life Sciences segment.
- Simply Wall St.•25 days ago
When Will Biome Grow Inc. (CNSX:BIO) Become Profitable?
Biome Grow Inc.'s (CNSX:BIO): Biome Grow Inc. focuses on cannabis growing business in Atlantic Canada region. The...
- Business Wire•26 days ago
Bio-Rad to Participate at Jefferies 2019 Global Healthcare Conference on June 4
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, at 10 AM , in New York, NY.
- Thomson Reuters StreetEvents•last month
Edited Transcript of BIO earnings conference call or presentation 8-May-19 9:00pm GMT
Q1 2019 Bio Rad Laboratories Inc Earnings Call
- Zacks•last month
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand
Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.
Motley Fool•last monthBio-Rad Laboratories Inc (BIO) Q1 2019 Earnings Call Transcript
BIO earnings call for the period ending March 31, 2019.
- Zacks•last month
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 47.32% and 0.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Bio-Rad: 1Q Earnings Snapshot
The Hercules, California-based company said it had net income of $28.74 per share. Earnings, adjusted for one-time gains and costs, came to $1.65 per share. The maker of instruments used in biomedical ...
- Business Wire•last month
Bio-Rad Reports First Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2019.
- Zacks•last month
Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?
Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).
- American City Business Journals•last month
Netflix and Google now pay a typical employee more than $200K per year. Here's how that compares to Facebook, Intel, Twitter and other big Bay Area tech employers.
Netflix and Google employees are now in Silicon Valley's $200K club. The typical Googler earned $246,804 last year — up 25 percent year-over-year. At Netflix, the median employee made $202,335 last year after getting a 10 percent pay boost over 2017.
- Zacks•2 months ago
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•2 months ago
CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.
- Zacks•2 months ago
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.
- Zacks•2 months ago
Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised
Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.
- Zacks•2 months ago
Boston Scientific (BSX) Misses Q1 Earnings, Tightens EPS View
Boston Scientific (BSX) is investing in new technologies and the global markets, which in turn, aids the uptick in sales across its most geographies in Q1.
- Zacks•2 months ago
Thermo Fisher (TMO) Beats on Q1 Earnings, Raises '19 View
Thermo Fisher (TMO) reports strong Laboratory Products and Services performance, flaunting robust global demand.
- Zacks•2 months ago
Accuray (ARAY) Q3 Earnings Top Estimates, Gross Orders Rise
Solid demand for Accuray's (ARAY) Radixact, CyberKnife and TomoTherapy platforms continue to boost business.
